Delhi gang rape: Minor accused to spend three years in reform home

August 31, 2013
New Delhi, Aug 31: The Juvenile Justice Board Saturday sentenced the lone minor accused in the Dec 16, 2012 gang rape here to a three-year stay in a special home. The boy, who was 17-and-half years old at the time of the incident, has turned 18. minor

The board, presided over by Principal Magistrate Geetanjali Goel, pronounced the verdict and acquitted him of some of the charges.

The incident occurred in Munirka in south Delhi when a 23-year-old woman physiotherapy intern was brutally gang raped in a bus that she and her male companion had boarded.

The victim had succumbed to injuries Dec 29, 2012 at Singapore's Mount Elizabeth Hospital, where she had been airlifted for specialised treatment.

The incident sparked protests across the country with some people demanding the execution of the accused and some calling for chemical castration.

Police in their charge sheet said the juvenile was the most brutal of all the accused.

A native of Uttar Pradesh, the minor had moved to Delhi at the age of 11 and was arrested after the incident from Anand Vihar in east Delhi.

Six people, including the juvenile, were arrested in the case. While accused Ram Singh, Mukesh, Pawan Gupta, Vinay Sharma and Akshay Thakur faced trial in fast track court in Saket in south Delhi, the juvenile's case was heard by the board.

The case against Ram Singh was dropped after he was found dead, hanging in his cell in Tihar Jail.

The Supreme Court Aug 22 allowed the board to go ahead with pronouncing its verdict after accepting Bharatiya Janata Party leader Subramanian Swamy's plea for a fresh interpretation of the term juvenile.

Swamy had moved the apex court saying that the "mental and intellectual maturity" of minor offenders be considered instead of the age limit of 18 years while fixing their culpability.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 22,2020

New Delhi, Jun 22: With an increase of 14,821 new cases and 445 deaths, India's COVID-19 count reached 4,25,282 on Monday.

According to the latest update by the Union Ministry of Health and Family Welfare (MoHFW), 13,699 deaths have been recorded due to the infection so far in the country.

The rise in confirmed cases today is lower than the highest spike of 15 thousand plus cases registered on Sunday.

The count includes 1,74,387 active cases, and 2,37,196 cured/discharged/migrated patients.

Maharashtra with 1,32,075 confirmed cases remains the worst-affected by the infection so far in the country. The state's count includes 60,161 active, 65,744 cured, discharged patients while 6,170 deaths have been reported due to the infection so far.

Meanwhile, the national capital today became the second-worst affected region in the country with the number of confirmed cases in Delhi reaching 59,746 as opposed to Tamil Nadu's 59,377 cases.

While 2,175 deaths have been reported in Delhi due to the infection so far, the toll in Tamil Nadu stands at 757.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 1,2020

Sopore, Jul 1: Police rescued a three-year-old boy from getting hit by bullets during a terrorist attack in Jammu and Kashmir's Sopore on Wednesday.

Earlier in the day, a Central Reserve Police Force (CRPF) jawan and a civilian lost their lives after terrorists fired upon a CRPF patrolling party in Sopore.

Two of the injured CRPF jawans are known to be in critical condition. Three CRPF personnel were also injured in the attack, as per CRPF.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.